Diagnose und Therapie des Mammakarzinoms

Wie in jedem Jahr hat auch in diesem Jahr die onkologische Fachwelt mit Spannung neue Therapiedaten von der 41. Jahrestagung der American Society of Clinical Oncology erwartet. Dabei haben das Mammakarzinom und die gynäkologischen Malignome wieder einmal einen breiten Raum eingenommen.

Literatur

• 1 Thürlimann B, Keshaviah A, Mouridsen H, Mauriac L, Forbes J F, Paridaens R, Castiglione-Gertsch M, Gelber R D, Smith I, Goldhirsch A. BIG 1-98: Randomized double-blind phase III study to evaluate letrozole vs. Tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Proc ASCO 2005, abstr. 511
• 2 Goldstein L, O'Neill A, Sparano J, Perez E, Shulman L, Martino S, Davidson N. E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. Proc ASCO 2005, abstr. 512
• 3 Wapnir I, Anderson S, Mamounas S, Geyer C, Hyeon-Jeong J, Constantino J, Fisher B, Wolmark N. Survival after IBTR in NSABP node negative protocols B-13, B-14, B-19, B-20 and B-23. Proc ASCO 2005, abstr. 517
• 4 Fisher B, Wickerham D L, Deutsch M, Anderson S, Redmond C, Fisher E R. Breast tumor recurrence following lumpectomy with and without breast irradiation: an overview of recent NSABP findings.  Semin Surg Oncol. 1992;  8 153-160
• 5 Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A. et al .European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression from adding pacalitaxel to doxorubicin followed by cyclophosphamide, methotrexate and fluorouracil. Proc ASCO 2005, abstr. 513
• 6 Gennari A, Conte P, Nanni O, Manzione L, Cortesi E, Boni C. et al .Multicenter randomized trial of paclitaxel maintenance chemotherapy versus control in metastatic breast cancer patients achieving a response or stable disease to first-line chemotherapy includine anthracyclines and paclitaxel: final results from the italian MANTA study. Proc ASCO 2005, abstr. 522
• 7 Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Lluch A. et al .Gemcitabine plus docetaxel versus capecitabine plus docetaxel for anthracycline-pretreated metastatic breast cancer patients: results of a European phase III study. Proc ASCO 2005, abstr. 581
• 8 Baxter N N, Virnig B A, Durham S B, Tuttle T M. Radiation after lumpectomy for DCIS to reduce the risk of invasive breast cancer: A population-based study. Proc ASCO 2005, abstr. 516
• 9 Harbeck N, Bohlmann I, Ross J S, Gruetzmann R, Kristiansen G, Margossian A, Hartmann A, Cufer T, Paradiso A, Maier S,. EpiBreast Group .Multicenter study validates PITX2 DNA methylation for risk prediction in tamoxifen-treated, node-negative breast cancer using paraffin-embedded tumor tissue. Proc ASCO 2005, abstr. 505
• 10 Sotiriou C, Wirapati P, Loi S, Desmedt C, Harris A L, Bergh J, Smeds J, Cardoso F, Delorenzi M, Piccart M. Molecular characterization of clinical grade in breast cancer (BC) challenges the existence of “grade 2” tumors. Proc ASCO 2005, abstr. 506
• 11 Porter P L, Barlow W, Yeh I -T, Lin M G, Yuan X, Ingle J N, Shapiro C L, Sledge G P, Livingston R B, Hayes D F. Prognostic value of cell cycle regulators p27 and cyclin E: Tissue microarray analysis of 1 753 women enrolled in SWOG breast cancer trial 9313. Proc ASCO 2005, abstr. 507